Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AMG 160 + unspecified PD-1 antibody |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AMG 160 | HLE-BiTE AMG 160|AMG-160|AMG160|Acapatamab | PSMA Antibody 22 | AMG 160 is a bi-specific T-cell engager (BiTE) antibody that binds to PSMA and CD3, potentially resulting in enhanced T-cell response and antitumor activity against PSMA-expressing tumor cells (PMID: 33504551). | |
| unspecified PD-1 antibody | Experimental PD-1 antibody | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|